• Mavorixafor hydrochloride Assay Guide

  2026-09-02

  This scenario-based guide explains how Mavorixafor hydrochloride, SKU A3174, can be integrated into CXCR4 signaling, viability, proliferation, and cytotoxicity workflows. It emphasizes concentration design, solvent compatibility, orthogonal readouts, assay interpretation, and evidence-based product selection.

• DOPE Workflows for Lipid Delivery and Ferroptosis

  2026-09-01

  DOPE is a membrane-fusion helper that strengthens cationic liposome and LNP strategies for cytoplasmic nucleic acid release. A recent Magnaporthe oryzae study also positions this phosphatidylethanolamine as an exploratory rescue reagent for connecting lipid metabolism, ferroptotic conidial death, and fungal pathogenicity.

• Idoxuridine Assay Design Through Causal Controls

  2026-09-01

  Idoxuridine and 5-iodo-2'-deoxyuridine provide a mechanistic framework for studying viral DNA synthesis inhibition. This guide develops a causal, orthogonal assay strategy that separates DNA replication disruption from host-cell injury and draws methodological insight from human-neuron pharmacology.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-08-31

  Tamoxifen is both a selective estrogen receptor modulator and a practical switch for temporally controlled genetic manipulation. This guide connects CreER-mediated gene knockout, breast cancer research, and pathway-focused cell assays with dose-aware controls informed by developmental safety findings.

• Deferasirox in Cell Assays: Practical Q&A

  2026-08-31

  This scenario-based guide explains how Deferasirox (SKU A8639) can be integrated into cell viability, proliferation, and cytotoxicity workflows while accounting for oxygen status, solvent compatibility, and iron-dependent biology. It connects practical assay design with recent ferroptosis research and provides evidence-linked guidance for selecting and interpreting Deferasirox experiments.

• Baricitinib and PSC: From Spatial Maps to Assays

  2026-08-30

  Baricitinib (LY3009104) provides a selective JAK1/2 perturbation strategy for testing IL-6-linked inflammation suggested by spatial proteomics in primary sclerosing cholangitis. This article translates tissue-level observations into compartment-aware assays while separating mechanistic evidence from therapeutic speculation.

• FGFR1 as a Druggable Target in Schizophrenia

  2026-08-29

  A 2025 Molecular Neurobiology study integrated drug-target Mendelian randomization, colocalization, SMR, PheWAS, molecular docking, and single-cell analysis to prioritize schizophrenia-associated druggable genes. FGFR1 emerged as the leading candidate, although the findings support target prioritization rather than a clinically validated treatment.

• GLP-1 (9-36) amide: Research Guide

  2026-08-28

  GLP-1 (9-36) amide is a research-grade glucagon-like peptide-1 receptor antagonist for controlled studies of GLP-1R signaling. Product specifications define its identity and handling requirements, while receptor-interplay research shows why matched controls are essential when interpreting cAMP assays.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-08-28

  Tamoxifen combines selective estrogen receptor modulator pharmacology with powerful temporal control in CreER models, making it useful for gene recombination, breast cancer research, and mechanism-focused cell studies. Reliable results depend on solvent handling, matched controls, and explicit testing for developmental or receptor-independent effects.

• Carfilzomib (PR-171): From Target to Translation

  2026-08-27

  Carfilzomib (PR-171) illustrates how irreversible proteasome engagement can become a translational strategy rather than a standalone assay result. This article connects proteasome-mediated proteolysis inhibition with endoplasmic reticulum stress, radiation sensitization, and coordinated apoptosis, paraptosis, and ferroptosis in esophageal squamous cell carcinoma research.

• Annexin V-Cy5 Apoptosis Kit: Signal Logic

  2026-08-27

  Learn how the Annexin V-Cy5 Apoptosis Kit separates phosphatidylserine exposure from reversible lysosomal stress in microglia. This evidence-based guide provides a decision-centered workflow for flow cytometry apoptosis detection and fluorescence microscopy apoptosis analysis.

• Saquinavir: From Protease Assay to Membrane Insight

  2026-08-26

  Saquinavir is a clinically established HIV protease inhibitor whose assay interpretation can be strengthened by separating antiviral target engagement from membrane-partition behavior. This article translates comparative IAM LC and LEKC evidence into a practical framework for HIV infection research, antiretroviral drug research, and carefully bounded translational studies.

• ABT-263 (Navitoclax): Practical Lab Workflow

  2026-08-26

  ABT-263 (Navitoclax) provides a high-affinity research tool for testing whether Bcl-2, Bcl-xL, and Bcl-w contribute to apoptotic resistance in cellular and preclinical cancer models. This dossier-based guide covers DMSO handling, apoptosis assay setup, and interpretation boundaries; it is not clinical dosing guidance or a substitute for matched paper validation.

• Force-Regulated Transport in Tunneling Nanotubes

  2026-08-25

  The reference study combines optical trapping, confocal imaging, microtubule-polarity mapping, and viscoelastic calibration to quantify lipid-droplet transport through tunneling nanotubes. Its force measurements show that kinesin and dynein cooperate as dynamically coupled motor ensembles, providing a mechanical explanation for bidirectional, long-range cargo movement in confined intercellular bridges.

• TCEP Hydrochloride: Mechanism and Workflows

  2026-08-25

  Tris(2-carboxyethyl) phosphine hydrochloride, also called TCEP hydrochloride, is a water-soluble, thiol-free reagent for disulfide bond reduction. Its product specifications support protein analysis, protein digestion enhancement, hydrogen-deuterium exchange analysis, and selected organic synthesis workflows, while current lateral-flow evidence supports capture-and-release concepts rather than direct validation of TCEP itself.

8105 records 1/541 page Next 12345 下5页 Last page